Andere Sprachen Mustang Bio, Inc.

Aktien

A3D9TV

US62818Q2030

MBIO

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
0,3161 ^USD	-9,79 %		-7,46 %	-76,59 %

28.03.	Mustang Bio, Inc. gibt Vision für die Ausweitung der CAR T-Zelltherapie-Plattform auf Autoimmunkrankheiten bekannt	CI
11.03.	Mustang Bio, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

North American Morning Briefing : Stock Futures Rise Despite Middle East Tensions	15.04.
Mustang Bio : Costs Associated with Exit/Disposal - Form 8-K	12.04.
Mustang Bio : Corporate Presentation	01.04.
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases	28.03.
Mustang Bio, Inc Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases	28.03.
Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights	11.03.
Mustang Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	11.03.
City of Hope-developed chimeric antigen receptor T cell therapy shows clinical activity in patients with aggressive brain tumors in a Phase 1 trial	08.03.
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma	07.03.
Mustang Bio, Inc. Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101IL13Ra2-targeted CAR T-Cells in High-Grade Glioma	07.03.
Mustang Bio : Corporate Presentation	01.03.
Mustang Bio, Inc Appoints James Murphy as Interim Chief Financial Officer	25.01.
Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference	11.01.
Mustang Bio, Inc. Appoints Peter Carney as the Interim Chief Accounting Officer	12.12.
Mustang Bio, Inc. Announces Executive Changes	12.12.
Mustang Bio Presents Updated Phase Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology Annual Meeting	12.12.
Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting	11.12.
Mustang Bio, Inc. Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology Annual Meeting	11.12.
Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights	14.11.
Mustang Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Mustang Bio, Inc.

Aktien

A3D9TV

US62818Q2030

MBIO

Andere Sprachen

Filter